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pared to adalimumab and infliximab when using actual drug utilization data from
US commercially-insured population.
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OBJECTIVES: Transfusion of allogeneic blood still is common in orthopedic surgery
albeit associated with higher morbidity and mortality. This analysis evaluates from
the perspective of a German hospital the potential cost savings of Epoetin alfa
compared to predonated autologous blood transfusions or to no-blood-conserva-
tion-strategy during elective hip and knee replacement surgery by reducing allo-
geneic blood transfusions and their associated infectious adverse events.
METHODS: Individual patients (n  10,000) were created based on data from con-
trolled trials, the German DRG institute (InEK) and various publications and entered
into a stochastic model (Monte-Carlo) one of three treatment arms: Epoetin alfa,
preoperative autologous donation and no-blood-conservation-strategy. The model
is focused on the costs and events of the procedure and follow-up. The model was
validated by an independent external consultant. Clinical and economical vari-
ables were obtained from clinical trial databases, the German DRG System, patient
records and medical publications- in particular cost per transfusion (allogeneic red
blood cells: € 320/unit and autologous red blood cells: € 280/unit), pneumonia treat-
ment (€ 5,000), and length of stay (€ 300/day). Probabilistic sensitivity analyses were
performed to determine which, if any, factors had an influence on the model’s
clinical and cost outcomes. RESULTS:At acquisition costs of € 375/40,000 IE Epoetin
alfa is cost saving compared to autologous blood donation, and at € 185/40,000 IE
compared to no-blood-conservation-strategy. The results were most sensitive to
the cost of Epoetin alfa, blood units and hospital days. CONCLUSIONS: Upcoming
shortages and increasing prices of red blood cells will make Epoetin alfa an attrac-
tive blood conservation strategy for anemic patients at reasonable costs, due the
reduction in allogeneic blood transfusions and their associated infectious adverse
events.
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OBJECTIVES: Biologics represent significant costs of rheumatic diseases treatment.
Our study has focused on productivity comparison of rheumatoid arthritis (RA)
patients treated with biologics and patients on DMARDs who are indicated to bio-
logic treatment however therapy is unavailable due to economic limitations.
METHODS: Work Productivity and Activity Impairment Questionnaire (WPAI:RA)
was administered to two groups of patients - patients treated with biologics (n76)
with low disease activity and patients just on DMARDs (n23) with high disease
activity (DAS28 score  5,1). All patients were in productive age. Patients’ demo-
graphics, clinical and PRO parameters (DAS28, HAQ, time from diagnosis) and
working statuses we collected by rheumatologist. Productivity costs were calcu-
lated by friction cost approach using friction period of 130 work-days and average
monthly gross income as denominator. RESULTS: Mean patients= age on biologics
and on DMARDs were 41.0 years (21-61) and 45.7 (22 – 61), respectively. Mean time
from diagnosis of biologics and DMARDs groups were 13.5 and 11.6 years, respec-
tively. Average HAQ and DAS28 were 0.77 and 2.64, respectively for patients on
biologics and 1.14, 5.62, respectively for patients on DMARDs. Patients on biologics
were slightly more work-disable (26.3%) compare to 25.0% DMARDs patients. Over-
all work-impairment (for patients that reported any work-impairment) for patients
on biologics and for patients on DMARDs was 28.1% and 49.6%, respectively. Pa-
tients on biologics reported less reduction of daily activities (39.8%) in compare to
patients on DMARDs (50.5%). Average annual productivity costs per one patient on
biologics and for DMARDs patient were € 1802 and € 2769, respectively.
CONCLUSIONS: Despite of the fact, patients on biologics had longer time from
diagnoses, they reported significantly lower work-impairment and reduction of
daily activities in compare to DMARDs patients, which reflected about 53.6% higher
productivity costs for patients on DMARDs. Biologic treatment preserves produc-
tivity and save productivity costs.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs. Costs are supposed to increase with increasing HAQ score.
Therefore, we calculated direct and productivity costs for five groups of patients
according to their HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assump-
tion also in the Czech Republic. METHODS: This calculation was based on a retro-
spective cross-sectional study. We included 126 patients with rheumatoid arthritis,
aged 18-84 years either at working status, part-time disabled or full-time disabled.
For estimation of direct medical costs, we used microcosting method retrospec-
tively reviewing individual patients’ medical records. For calculation of productiv-
ity costs we excluded patients older than 63 years of age (retirement pensioners).
We used friction costs approach (FCA) with defined friction period of 130 workdays,
based on patients’ absenteeism. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 52% and 70%, respectively,
based on the Czech law on pension insurance. The height of average monthly
income in year 2010, €960.3 was used as denominator. Costs were expressed as
mean value per one patient with RA in each of the HAQ-group. RESULTS: Average
patients= age was 57.3 years; average time from diagnosis was 17.5 years with mean
HAQ score 1.4 and mean DAS28 3.62. Mean annual medical direct costs, for each
HAQ-group, were €4076.7, €5950.2, €4691.3, €6932.1, and €6727.1, respectively. Mean
annual indirect costs associated with productivity loss were €481.5, €1178.6,
€1267.7, €1585.6, and €2122.5, respectively. CONCLUSIONS: Direct and productivity
costs for patients with rheumatoid arthritis are closely related to the height of HAQ
score. Total (direct and productivity) annual mean costs were €7135.6. 31.0% of all
patients were treated with biological treatment which represented up to 79.4% of
the overall direct medical costs.
PMS19
THE ECONOMIC BURDEN OF POST-MENOPAUSAL OSTEOPOROSIS AND
RELATED FRACTURES IN GREECE
Athanasakis K1, Karampli E1, Hollandezos M1, Papagiannopoulou V2, Badamgarav E3,
Intorcia M4, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2AMGEN Hellas, Marousi, Greece, 3Amgen,
Thousand Oaks, CA, USA, 4Amgen S.A., Barcelona, Spain
OBJECTIVES: To determine the healthcare resource use (HRU) and costs attribut-
able to osteoporosis and osteoporosis-related fractures in post-menopausal
women in Greece METHODS: A multi-point data collection procedure, based on
strictly-structured interviews with 137 geographically distributed physicians, was
used to construct and populate the disease management model for women with
post-menopausal osteoporosis (PMO) aged 50years. The model was further vali-
dated by a group of 12 experts. Secondly, all HRU items in the model were costed in
order to provide per-patient costs of treatment. Cost variables included costs of
consultations, laboratory tests, osteoporotic medication, dietary supplements,
hospitalization due to fractures and rehabilitation, allcalculated from a third-party
payer perspective (Euros, 2011) for a 1year timeframe (retrospective).RESULTS:The
mean annual cost per PMO patient was €1,384.67 (95%CI: 423.27 – 7281.16). When
distinguishing between women with established (PMO with a previous fracture)
(27.6% of total) and non-established PMO, the mean annual cost per patient was
€2027.46 (95%CI: 508.09-7241.90) and €1139.63 (95%CI: 461.86 - 1324.44) respectively.
For PMO women with an established osteoporosis for1year the mean annual cost
was significantly higher compared to those with an established osteoporosis for 
1year €2714.98 (95%CI: 820.17 – 7284.42) versus €1805.54 (95%CI: 508.09 – 7241.77).
The mean annual cost per patient with a fracture was €4,334.27 (95%CI: 1,452.86 –
10,730.17) for a hip, €2,723.27 (95%CI: 1,470.39 – 7,839.55) for a vertebral and
€1,731.35 (95%CI: 1,131.17 - 1,942.48) for a Colles fracture respectively. The sensi-
tivity analysis (10% change of baseline values) showed that the factors with the
greatest impact on total cost were the probability of established osteoporosis, the
probability of a fracture in the previous 12 months, cost of parathormone treatment
and the cost of patient monitoring. CONCLUSIONS: Treatment of osteoporosis is
costly. Efforts to control the main osteoporosis cost drivers and hence its economic
impact on the health care budgets, are necessary.
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OBJECTIVES: Psoriasis (prevalence 2-3%) is not directly life-threatening disease.
However, patients suffering from psoriasis and psoriatic arthritis (PsA) are experi-
encing lower quality of life. Treatment of these diseases represents a significant
financial burden for the healthcare system. METHODS: Study was based on 12-
months retrospective electronic questionnaire reported by dermatologist. We used
societal perspective using friction cost approach method for productivity costs
calculation. Patients’ demographics, clinical data (PASI and BSA index), direct costs
(inpatient/outpatient care, local/systemic treatment etc.), productivity costs (inva-
lidity, sick leave) and on QoL (EQ-5D, DLQI) were collected. RESULTS: A total of 256
patients participated in the study, average patients= age was 46.79 years (9-75
years), average time from diagnosis was 25.52 years with average PASI 13,76, BSA
28,09%, DLQI 11,74 and EQ-5D 0,7633. Occurrence of PsA was 34.4%. Major direct
costs driver was phototherapy (47% of direct costs), systematic treatment (17%) and
inpatient care (15%). Within the productive-age patients (18-63 years), 8.6% of pa-
tients were fully disabled, 7.4% partially disabled, 73% patients were work-active,
and 11% were unemployed, retired or students. 17.2% of work-active patients re-
ported incapacity to work with average duration of 33 days in previous 6 months.
Mean indirect costs associated with productivity loss were €848.3 per work-active
patient per year €1343.0 per work-active patient with PsA. Mean annual costs per
patient with moderate to severe psoriasis and/or PsA were calculated to €3736.5
(direct costs 77%, €2888.2). Mean annual costs per patient with PsA were €4328.3
including €2985.3 for direct costs (69%). CONCLUSIONS: Direct costs remain major
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